HomeCompareCMGR vs ABBV

CMGR vs ABBV: Dividend Comparison 2026

CMGR yields 2000000.00% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMGR wins by $4.879226400974806e+39M in total portfolio value
10 years
CMGR
CMGR
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full CMGR calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CMGR vs ABBV

📍 CMGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMGRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMGR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMGR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMGR
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, CMGR beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMGR + ABBV for your $10,000?

CMGR: 50%ABBV: 50%
100% ABBV50/50100% CMGR
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CMGR
No analyst data
Altman Z
1854.5
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMGR buys
0
ABBV buys
0
No recent congressional trades found for CMGR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMGRABBV
Forward yield2000000.00%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.879226400974806e+39M$104.7K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$25,725.73
Total dividends collected$4.879195005460081e+39M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CMGR vs ABBV ($10,000, DRIP)

YearCMGR PortfolioCMGR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,559$438.51+$200.00MCMGR
2$3,738,731,768,458$3,738,517,757,009.35$13,494$640.86+$3738731.75MCMGR
3$65,315,062,866,930,490$65,311,062,423,938,240.00$15,951$945.97+$65315062866.91MCMGR
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$19,152$1,413.89+$1066400830062625.00MCMGR
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$23,443$2,146.38+$16272182796453826560.00MCMGR
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$29,391$3,321.96+$2.3205424011366188e+23MCMGR
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$37,948$5,265.87+$3.0927990661046884e+27MCMGR
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$50,795$8,596.74+$3.8524105697352695e+31MCMGR
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$71,034$14,549.41+$4.484688260147987e+35MCMGR
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$104,715$25,725.73+$4.879226400974806e+39MCMGR

CMGR vs ABBV: Complete Analysis 2026

CMGRStock

Clubhouse Media Group, Inc. operates professionally run content houses that provides management, production, and deal-making services to influencers worldwide. The company is involved in the talent management of social media influencers; content-creation studio, social media marketing, technology development, and brand incubation; provision of predictive analytics for content creation brand deals; and paid promotion. It also offers talent management and brand partnership deals to external influencers. The company was formerly known as Tongji Healthcare Group, Inc. to Clubhouse Media Group, Inc. in January 2021. Clubhouse Media Group, Inc. was incorporated in 2006 and is headquartered in Las Vegas, Nevada.

Full CMGR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CMGR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMGR vs SCHDCMGR vs JEPICMGR vs OCMGR vs KOCMGR vs MAINCMGR vs JNJCMGR vs MRKCMGR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.